Matthew Biegler
Stock Analyst at Oppenheimer
(1.72)
# 3,059
Out of 4,681 analysts
76
Total ratings
27.27%
Success rate
-8.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Maintains: Outperform | $50 → $40 | $25.72 | +55.52% | 3 | Oct 31, 2024 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $53 | $27.45 | +93.08% | 5 | Oct 29, 2024 | |
| TYRA Tyra Biosciences | Maintains: Outperform | $25 → $33 | $15.86 | +108.07% | 6 | Sep 19, 2024 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Outperform | $20 | $3.66 | +446.45% | 7 | Sep 16, 2024 | |
| RLAY Relay Therapeutics | Downgrades: Perform | n/a | $4.67 | - | 6 | Sep 10, 2024 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $17 → $15 | $10.17 | +47.49% | 4 | Aug 13, 2024 | |
| ALLO Allogene Therapeutics | Assumes: Outperform | $13 → $11 | $2.55 | +331.37% | 1 | Aug 8, 2024 | |
| OLMA Olema Pharmaceuticals | Reiterates: Outperform | $30 | $10.21 | +193.83% | 4 | Aug 7, 2024 | |
| BPMC Blueprint Medicines | Maintains: Outperform | $114 → $125 | $97.62 | +28.05% | 5 | Jul 8, 2024 | |
| RNAC Cartesian Therapeutics | Downgrades: Peer Perform | n/a | $19.57 | - | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $3.88 | +260.82% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 → $10 | $0.87 | +1,050.75% | 6 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $5.20 | - | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $2.96 | - | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $13.84 | - | 2 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $15 | $0.18 | +8,052.17% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $7.44 | +236.02% | 1 | Jun 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.03 | - | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.97 | - | 2 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $520 → $360 | $4.04 | +8,810.89% | 1 | Nov 30, 2022 |
Arvinas
Oct 31, 2024
Maintains: Outperform
Price Target: $50 → $40
Current: $25.72
Upside: +55.52%
IDEAYA Biosciences
Oct 29, 2024
Reiterates: Outperform
Price Target: $53
Current: $27.45
Upside: +93.08%
Tyra Biosciences
Sep 19, 2024
Maintains: Outperform
Price Target: $25 → $33
Current: $15.86
Upside: +108.07%
Zentalis Pharmaceuticals
Sep 16, 2024
Reiterates: Outperform
Price Target: $20
Current: $3.66
Upside: +446.45%
Relay Therapeutics
Sep 10, 2024
Downgrades: Perform
Price Target: n/a
Current: $4.67
Upside: -
ORIC Pharmaceuticals
Aug 13, 2024
Maintains: Outperform
Price Target: $17 → $15
Current: $10.17
Upside: +47.49%
Allogene Therapeutics
Aug 8, 2024
Assumes: Outperform
Price Target: $13 → $11
Current: $2.55
Upside: +331.37%
Olema Pharmaceuticals
Aug 7, 2024
Reiterates: Outperform
Price Target: $30
Current: $10.21
Upside: +193.83%
Blueprint Medicines
Jul 8, 2024
Maintains: Outperform
Price Target: $114 → $125
Current: $97.62
Upside: +28.05%
Cartesian Therapeutics
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $19.57
Upside: -
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $3.88
Upside: +260.82%
May 13, 2024
Reiterates: Outperform
Price Target: $15 → $10
Current: $0.87
Upside: +1,050.75%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $5.20
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $2.96
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $13.84
Upside: -
Aug 11, 2023
Maintains: Outperform
Price Target: $50 → $15
Current: $0.18
Upside: +8,052.17%
Jun 2, 2023
Initiates: Outperform
Price Target: $25
Current: $7.44
Upside: +236.02%
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $3.03
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.97
Upside: -
Nov 30, 2022
Maintains: Outperform
Price Target: $520 → $360
Current: $4.04
Upside: +8,810.89%